WHITE PAPER
Inclusion of Obese Individuals in Early Phase Healthy Volunteer Trials
Jun 14, 2024
Download

Authored by an IQVIA expert, this white paper explores considerations for including participants defined as obese based on their BMI in early-phase clinical trials. It delves into the pathophysiological changes associated with obesity that can influence a drug’s pharmacological profile, the regulatory landscape, and the use of tools such as in silico modeling and population pharmacokinetic analysis (PopPK).

Related solutions

Contact Us